Sangamo Therapeutics (NASDAQ:SGMO) Receives Buy Rating from HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Sangamo Therapeutics (NASDAQ:SGMO – Free Report) in a research note ...
Brokerages Set Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Price Target at $5.17
Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Get Free Report) have been assigned a consensus recommendation of ...
Sangamo Therapeutics Stock Crashes as Pfizer Ends Hemophilia Drug Pact
Sangamo Therapeutics shares lost more than half their value when Pfizer pulled out of a collaboration agreement.
Expert Outlook: Sangamo Therapeutics Through The Eyes Of 11 Analysts
Analysts have recently evaluated Sangamo Therapeutics and provided 12-month price targets. The average target is $8.09, accompanied by a high estimate of $10.00 and a low estimate of $2.00. Surpassing ...
MarketWatch1mon
Sangamo Therapeutics’ stock falls the most in 16 years after Pfizer ends hemophilia pact
Editor’s note: A breaking-news bulletin linked to this story inaccurately characterized the number of years that have passed since Sangamo Therapeutics shares lost as much in a single session.
Sangamo Biosciences Receives ‘Buy’ Rating from Patrick Trucchio Amid Anticipated Collaborations and Gene Therapy Advances
H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Sangamo Biosciences (SGMO – Research Report) today and set a price target ...
Yahoo Finance7d
Sangamo Therapeutics, Inc. (SGMO)
RICHMOND, Calif., December 30, 2024--SANGAMO THERAPEUTICS TO REGAIN FULL RIGHTS TO HEMOPHILIA A GENE THERAPY PROGRAM FOLLOWING PFIZER’S DECISION TO CEASE DEVELOPMENT Astellas Pharma Inc. (TSE ...
Nasdaq4d
Expert Outlook: Sangamo Therapeutics Through The Eyes Of 11 Analysts
In the last three months, 11 analysts have published ratings on Sangamo Therapeutics (NASDAQ:SGMO), offering a diverse range of perspectives from bullish to bearish. The table below provides a ...